Novavax expects post-marketing Covid study to cost up to $90M

Novavax expects post-marketing Covid study to cost up to $90M

Novavax says conducting a post-marketing study for its Covid-19 vaccine will cost between $70 million and $90 million, following the FDA's more stringent approval framework that strongly advised the company to produce more efficacy data ...